Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Summary

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.

Timeline

Start

2024-12-16

Primary completion

2027-05-20

Completion

2027-05-20

Drugs

Indications